Shots:Pfizer has entered into a definitive agreement to acquire Metsera, expanding to obesity & cardiometabolic marketAs per the deal, Metsera will receive $47.5/share, representing an enterprise value of…
Digital transformation of the pharmaceutical industry is moving beyond buzzwords to real-world impact. At the Pharmaceutical Automation & Digitalisation Congress AUTOMA+ 2025 (24-25 November, Vösendorf, Austria), pharma leaders, including ZETA…
Shots: ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders. …
Shots:The US FDA has approved Keytruda Qlex (pembrolizumab & berahyaluronidase alfa-pmph) for subcutaneous dosing in adults across 38 approved indications of Keytruda, with US availability expected by late Sep 2025Approval…
Shots:The P-III (evERA Breast Cancer) trial evaluated giredestrant + everolimus vs SoC ET + everolimus in ER+, HER2-, LA/M breast cancer pts previously treated with CDK4/6 inhibitors & endocrine…
Shots:The CHMP has recommended Enflonsia to prevent RSV lower respiratory tract disease in newborns & infants entering their first RSV season, with potential approval valid in all 30 EEA…
Shots: Alkem Laboratories has launched Pertuza 420mg/14mL, a Perjeta biosimilar, across India for treating HER2-positive breast cancer In a P-III trial, Pertuza showed equivalent efficacy, safety, and immunogenicity to the reference…
Shots:The US FDA has approved the Altaviva device, an implantable tibial neuromodulation therapy to treat urge urinary incontinenceAltaviva device is placed under the skin above the fascia & near…
Shots:The CHMP has recommended Nipocalimab as an add-on therapy to treat anti-AChR Ab+ & anti-MuSK Ab+ gMG pts (≥12yrs.)Opinion was based on the P-III (Vivacity-MG3) trial assessing nipocalimab (30mg/kg,…
